Dicerna Pharma Closes on $8.4 Million

Dicerna Pharmaceuticals Inc, an RNA interference company based in Combridge, Mass., held a second closing on its Series A financing worth $8.4 million. Abingworth and existing investors Oxford Bioscience Partners and Skyline Ventures participated. The Series A round has collected $21.4 million to date. Company Web site